Hepatocellular carcinoma: epidemic and treatment.
Hepatocellular carcinoma remains a worldwide epidemic. Survival rates are poor; however, oncologists are able to offer regional therapies to those patients who present with early disease. Prevention through vaccination remains a mainstay of this epidemic. New staging systems that incorporate important information about tumor characteristics and liver disease improve our ability to prognosticate and treat these patients.
Allen
Jill
J
Division of Gastrointestinal Oncology, University of California at San Francisco School of Medicine, UCSF Medical Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115-1610, USA.
Venook
Alan
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods; D016461:Chemoembolization, Therapeutic / Q000379:methods; D006498:Hepatectomy / Q000379:methods; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006526:Hepatitis C / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
D017325:Hepatitis B Vaccines